STOP Persistent AF
Medtronic Cryocath, LP · Decision date Sep 25, 2026
What did the FDA approve?
FDA records P100010/S154 as a supplement to PMA P100010, with the supplement type “Normal 180 Day Track No User Fee”. The recorded decision is approval, dated Sep 25, 2026.
FDA approval order statement
approval of the early termination for the post-approval study (PAS) referenced above.
- Regulatory pathway
- PMA supplement
- Supplement type
- Normal 180 Day Track No User Fee
- Clinical specialty
- Cardiovascular
- Decision date
- Sep 25, 2026
- FDA change category
- Postapproval Study Protocol
Regulatory record facts
- Identifier
- P100010/S154
- Regulatory pathway
- PMA supplement
- Applicant
- Medtronic Cryocath, LP
- Product code
- OAE
- Decision code
- APPR
- Decision date
- Sep 25, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Catheter, percutaneous, cardiac ablation, for treatment of atrial fibrillation.
- Applicant
- Medtronic Cryocath, LP
- Product code
- OAE
- FDA device class
- 3
For the original device and its historical approval scope, see PMA P100010. Subsequent supplements may change the device or its indications.
FDA decision timeline
P100010 · Original PMA
ARCTIC FRONT CRYOCATHETER SYSTEM
P100010/S154 received
Application receipt date recorded by FDA.
P100010/S154 · FDA decision
Normal 180 Day Track No User Fee
Timeline entries are records held by MedtechLedger for P100010. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P100010
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| Medtronic Cryocath, LP | PMA approval | Dec 17, 2010 | FDA |
Explore the linked device profile
Other records with product code OAE
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
TactiFlex Ablation Catheter, Sensor EnabledP220013/S034 | ABBOTT MEDICAL | PMA supplement | Sep 22, 2026 | FDA |
| Biosense Webster, Inc. | PMA supplement | Sep 15, 2026 | FDA | |
QDOT MICRO SystemP210027/S018 | Biosense Webster, Inc. | PMA supplement | Sep 10, 2026 | FDA |
| ABBOTT MEDICAL | PMA supplement | Sep 4, 2026 | FDA | |
| ABBOTT MEDICAL | PMA approval | May 18, 2023 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Medtronic Cryocath, LP
- Headquarters
- Not reported
- Brand website
- medtronic.com
- FDA applicant address
- 8200 Coral Sea St., Ms Mv S46, Mounds View, MN, 55112
Sources and methodology
- Original FDA record: P100010/S154
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 19, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records
